It is estimated that there will be more than 900,000 new cases of non- melanoma skin cancer (NMSC) diagnosed in the U.S. in 1997, accounting for approximately 40% of all cancer diagnoses. melanoma will account for 1-3% of new cancer cases (40,300 cases in 1997) but the incidence and mortality rates are increasing more rapidly than any other invasive cancer. Continued increases in NMSC are expected as the population ages and as larger amounts of UV radiation reach the earth's surface because of the depletion of the ozone layer. The overall goal of our Chemopreventative of Skin Cancer Program Project is to develop safe and highly efficacious intervention strategies for prevention of melanoma and non-melanoma skin cancers and to develop basic science and clinical research approaches which will serve as models for the chemoprevention of a wide range of human epithelial cancers. Our Program Project consists of four scientific research components designed by an outstanding group of dedicated skin carcinogenesis scientists to address our primary hypothesis-that chemopreventive agents can alter the natural history of skin cancer. . Preclinical studies of mechanisms of UV-induced carcinogenesis and mechanisms of action of topically applied chemoprevention agents in melanoma and NMSC animal models. . Clinical studies to establish the validity and reproducibility of histopathologic, morphometric, genetic, and immunohistochemical surrogate endpoint biomarkers, in participants with preclinical actinic keratoses, actinic keratoses, cutaneous squamous cell cancers, and dysplastic nevi. . Sequential phase IIa and IIb randomized double-blinded, placebo- controlled skin cancer prevention studies of chemoprevention agents selected because of their mechanistic effects on the skin carcinogenesis signal transduction pathway as well as documented activity in UVB skin carcinogenesis and transgenic melanoma animal models. . In depth evaluation of possible correlations between changes in histopathology/morphometry and alterations in genetic expressions (as evaluated by cDNA microarray and immunohistochemical assays in human epidermal tissue biopsies.
| Blohm-Mangone, Karen; Burkett, Nichole B; Tahsin, Shekha et al. (2018) Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice. Cancer Prev Res (Phila) 11:265-278 |
| Knights-Mitchell, Shellie S; Romanowski, Marek (2018) Near-Infrared Activated Release of Doxorubicin from Plasmon Resonant Liposomes. Nanotheranostics 2:295-305 |
| Roh, Eunmiri; Lee, Mee-Hyun; Zykova, Tatyana A et al. (2018) Targeting PRPK and TOPK for skin cancer prevention and therapy. Oncogene 37:5633-5647 |
| Chen, Yin; Vasquez, Monica M; Zhu, Lingxiang et al. (2017) Effects of Retinoids on Augmentation of Club Cell Secretory Protein. Am J Respir Crit Care Med 196:928-931 |
| Yamamoto, Hiroyuki; Ryu, Joohyun; Min, Eli et al. (2017) TRAF1 Is Critical for DMBA/Solar UVR-Induced Skin Carcinogenesis. J Invest Dermatol 137:1322-1332 |
| Zykova, Tatyana A; Zhu, Feng; Wang, Lei et al. (2017) The T-LAK Cell-originated Protein Kinase Signal Pathway Promotes Colorectal Cancer Metastasis. EBioMedicine 18:73-82 |
| Einspahr, Janine G; Curiel-Lewandrowski, Clara; Calvert, Valerie S et al. (2017) Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light. NPJ Precis Oncol 1: |
| Gao, Ge; Zhang, Tianshun; Wang, Qiushi et al. (2017) ADA-07 Suppresses Solar Ultraviolet-Induced Skin Carcinogenesis by Directly Inhibiting TOPK. Mol Cancer Ther 16:1843-1854 |
| Glazer, Evan S; Bartels, Peter H; Lian, Fangru et al. (2016) Quantitative histopathology identifies patients with thin melanomas who are at risk for metastases. Melanoma Res 26:261-6 |
| Franklin, Stephen J; Younis, Usir S; Myrdal, Paul B (2016) Estimating the Aqueous Solubility of Pharmaceutical Hydrates. J Pharm Sci 105:1914-1919 |
Showing the most recent 10 out of 395 publications
